Peptide supplements in sports medicine

A scoping review out of UCLA's Department of Orthopaedic Surgery, published in the American Journal of Sports Medicine on August 11, 2026, is one of the more useful things written this year on the peptide trend moving from anti-aging clinics into mainstream sports medicine. Tewari and colleagues looked at six peptides marketed for recovery and performance, including BPC-157 and CJC-1295, and their conclusion is blunt^[1]: animal data is often promising, human evidence is scarce, and some of these compounds carry real safety signals that clinic marketing tends to leave out.

What the review looked at

The six peptides in the scoping review are BPC-157, thymosin beta-4 (the molecule sold in grey-market form as TB-500), CJC-1295, MK-677 (ibutamoren), ipamorelin, and GHK-Cu. Four of the six work through the growth-hormone axis in one way or another. CJC-1295 and ipamorelin both push the pituitary to release more growth hormone, through different receptors^[1]. BPC-157 and thymosin beta-4 work on tissue repair and blood-vessel growth rather than hormone signaling. None of the six holds a marketing authorization for any of the recovery or performance uses being discussed in sports-medicine clinics.

The authors ran a scoping review, not a meta-analysis, which is the right tool when a field has more marketing than trial data. Roughly two-thirds of the publications they found relied on preclinical animal models^[1]. Human clinical work existed for only a handful of the six peptides, and where it did exist, the review describes it as generally lacking rigorous methodology, meaning small samples, no control arm, or short follow-up. That gap between what is claimed in a clinic brochure and what has actually been tested in people is the paper's central finding.

CJC-1295 shows what the human data actually looks like

CJC-1295 is a useful case study because it has more human data than most of the other five. The original human pharmacokinetic work, published by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006, gave healthy adults ascending subcutaneous doses of the albumin-binding form of the peptide and reported a half-life of 5.8 to 8.1 days, growth-hormone concentrations 2 to 10 times baseline for six days or longer, and IGF-1 elevations of 1.5 to 3 times baseline lasting 9 to 11 days^[3]. That study, and a companion paper the same year, are essentially the entire human evidence base for CJC-1295. The clinical program stopped after early-phase work and never reached a completed phase-2 efficacy trial in any indication.

A separate 2026 primer for orthopaedic and sports-medicine physicians, also published in the American Journal of Sports Medicine, reviewed the same peptide and reported that CJC-1295 combined with ipamorelin improved muscle tension in mice with glucocorticoid-induced muscle loss, but the authors were direct about the limits: 'information regarding the indications, dosing, frequency, and duration of treatment remains unknown'^[2]. A mouse finding is not a reason to expect the same result in an injured athlete, and neither review treats it that way.

Regulatory status matches the thin evidence base. The FDA has not approved a human drug product containing CJC-1295. The only listing on DailyMed is a bulk ingredient for veterinary compounding, not a product cleared for use in people^[4]. Details on jurisdiction-by-jurisdiction status are on the CJC-1295 regulation page.

What the review is not saying

The review is not a warning to avoid every peptide forever, and it is not an endorsement either. Where the authors did find a human signal, they described it as modest at best, for outcomes like metabolic bone health and degenerative knee pain^[1]. They also flagged that some of the six compounds have been linked to serious complications, including congestive heart failure and metabolic disturbances such as impaired glucose handling; the abstract does not break out which specific peptide produced which complication, so that detail needs the full paper rather than the summary. Growth-hormone-axis peptides such as tesamorelin have a labeled adverse-event profile that includes fluid retention and glucose changes in their one approved indication, HIV-associated lipodystrophy, which is a plausible reason those risk categories would surface again in a related compound.

The authors' bottom line is that despite encouraging animal data, none of the six peptides currently has enough human evidence to replace established orthopedic and sports-medicine treatment. That is a narrower claim than 'these peptides are dangerous' or 'these peptides work.' It is closer to: the trial record has not caught up with the marketing.

Practical context

Tesamorelin is the one peptide in this cluster with an actual FDA approval, and only for one indication. Everything else discussed here, including CJC-1295, ipamorelin, BPC-157, and TB-500, remains an unapproved product with a human evidence base thinner than the online marketing implies. If you are weighing any of these for injury recovery or performance, that decision belongs with a clinician who can look at your history, not a vendor product page.